Bacterial actifensin kills by binding lipid II like eukaryotic defensins, revealing a shared evolutionary mechanism | Research

The takeaway

Actifensin from A. ruminicola kills gram-positive bacteria by binding lipid II (Kd=30 nM) without membrane disruption, is non-toxic and non-immunogenic in human cells, and belongs to a conserved GXGCP defensin motif shared across bacteria and eukaryotes.

Trans-kingdom defensin conservation
Bacterial actifensin uses the same lipid II-binding mechanism as eukaryotic defensins, revealing a 2+ billion year conserved antimicrobial strategy with excellent safety

What the researchers found

Actifensin binds lipid II (Kd=30 nM) and lipid I (Kd=24 nM). No membrane disruption. Cell death via cell wall weakening. No hemolysis or cytotoxicity up to 128 µg/ml. No immunogenicity (LDH, TLR signaling). GXGCP motif conserved trans-kingdom.

Why it matters

Finding that bacterial and eukaryotic defensins share the same killing mechanism validates lipid II as a universal antimicrobial target. Actifensin's safety profile (non-toxic, non-immunogenic) makes it an attractive antibiotic candidate.

How the study worked

Lipid II/I binding assays. DiSC3(5) fluorescence (membrane integrity). Liposome disruption. Phase contrast microscopy. Hemolysis. HepG2 cytotoxicity. PBMC immunogenicity (LDH, TLR signaling). Structural motif analysis.

What this study cannot tell us

In vitro characterization only. Gram-positive spectrum may limit clinical applications. In vivo efficacy not tested. Production scalability unknown.

How to read the evidence

Comprehensive in vitro characterization with structural, functional, and safety data. Strong mechanistic evidence.

When this study was published

Published in 2025.

The bigger picture

The discovery that defensin mechanism is conserved from bacteria to humans reveals a 2+ billion year evolutionary conservation of antimicrobial strategy—and provides a template for engineering new antibiotics based on this ancient mechanism.

Questions still open

Could actifensin or its derivatives become clinical antibiotics?
Would engineering the GXGCP motif improve potency?
Does the lipid I binding (unique vs eukaryotic defensins) provide additional killing advantage?

Common questions

What is actifensin?

Actifensin is an antimicrobial peptide produced by a gut bacterium (Actinomyces ruminicola). It kills harmful bacteria by blocking cell wall construction—the same mechanism used by defensin peptides in humans and other animals. This shared strategy has been conserved for over 2 billion years of evolution.

Could this become a new antibiotic?

It has strong potential. Actifensin showed no toxicity to human cells, no immune activation, and no hemolytic activity even at high doses. Its mechanism—blocking cell wall synthesis by binding lipid II—is fundamentally different from most existing antibiotics, making bacterial resistance unlikely.

Read the original research

Trans-kingdom conservation of mechanism between bacterial actifensin and eukaryotic defensins.

npj antimicrobials and resistance, 3(1), 66

View on PubMed ↗Publisher’s paper ↗

Citation

Sugrue, Ivan; Ade, Carolin; O'Connor, Paula M; Daniel, Jan-Martin; Innocenti, Paolo; Kirsch, Nico; Martin, Nathaniel I; Weindl, Günther; Hill, Colin; Schneider, Tanja; Paul Ross, R. (2025). Trans-kingdom conservation of mechanism between bacterial actifensin and eukaryotic defensins.. npj antimicrobials and resistance, 3(1), 66. https://doi.org/10.1038/s44259-025-00135-x